The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.

The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.

Liver stiffness measurement (LSM) using transient elastography has been proposed to assess liver fibrosis well in various liver diseases. This study was to determine the changes of LSM and its associated factors for chronic hepatitis B (CHB) patients undergoing Entecavir therapy. Consecutive CHB pat...

Full description

Bibliographic Details
Main Authors:	Yuan-Hung Kuo, Sheng-Nan Lu, Chien-Hung Chen, Kuo-Chin Chang, Chao-Hung Hung, Wei-Chen Tai, Ming-Chao Tsai, Po-Lin Tseng, Tsung-Hui Hu, Jing-Houng Wang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3969320?pdf=render

Similar Items

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
by: Te-Ling Ma, et al.
Published: (2019-01-01)

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
by: Hsin-Wei Fang, et al.
Published: (2024-04-01)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
by: Tzu-Ning Tseng, et al.
Published: (2022-05-01)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
by: Yu-Chi Lee, et al.
Published: (2019-01-01)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
by: Yi-Hao Yen, et al.
Published: (2018-01-01)

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
by: Jing‐Houng Wang, et al.
Published: (2019-11-01)

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
by: Te-Sheng Chang, et al.
Published: (2021-01-01)

Liver stiffness measurement in cirrhotic patient — Implications of disease activity and treatment efficacy
by: Huang-Wei Xu, et al.
Published: (2012-12-01)

HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
by: Kuo-Chin Chang, et al.
Published: (2022-11-01)

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Ming-Chao Tsai, et al.
Published: (2021-09-01)

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
by: Chao-Min Huang, et al.
Published: (2017-01-01)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
by: Yuan-Hung Kuo, et al.
Published: (2022-08-01)

On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
by: Hung-Wei Wang, et al.
Published: (2020-05-01)

Reversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral Therapy
by: Yuan-Hung Kuo, et al.
Published: (2011-06-01)

Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations
by: Po-Lin Tseng, et al.
Published: (2013-07-01)

Well‐controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib
by: Ya‐Wen Hsiao, et al.
Published: (2023-12-01)

Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function.
by: Tai-Long Chien, et al.
Published: (2016-01-01)

Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study.
by: Ming-Chao Tsai, et al.
Published: (2016-01-01)

Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study
by: Yi-Hao Yen, et al.
Published: (2018-09-01)

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
by: Chao-Hung Hung, et al.
Published: (2016-04-01)

Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
by: Yi-Hao Yen, et al.
Published: (2019-01-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease
by: Yi-Hao Yen, et al.
Published: (2018-04-01)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
by: Sheng Feng Lin, et al.
Published: (2020-01-01)

Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
by: Guei-Ying Chen, et al.
Published: (2015-11-01)

Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C
by: Chao-Hung Hung, et al.
Published: (2014-08-01)

Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community.
by: Yuan-Hung Kuo, et al.
Published: (2016-01-01)

Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case
by: Ming-Hung Wang, et al.
Published: (2021-06-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C
by: Sheng-Hung Chen, et al.
Published: (2018-04-01)

Sorafenib use in hepatitis B virus‐ or hepatitis C virus‐related hepatocellular carcinoma: A propensity score matching study
by: Yu‐Chi Lee, et al.
Published: (2021-10-01)

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation
by: Chih-Chien Yao, et al.
Published: (2023-02-01)

Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients
by: Chuan-Mo Lee, et al.
Published: (2016-06-01)

Hepatitis C core antigen highly correlated to HCV RNA
by: Christine Chang, et al.
Published: (2018-12-01)

Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels.
by: Cheng-Kung Wu, et al.
Published: (2016-01-01)

Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection
by: Ming-Chao Tsai, et al.
Published: (2019-12-01)

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
by: Yuan-Hung Kuo, et al.
Published: (2023-06-01)

Reply to “Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy”
by: Meng-Ju Lin, et al.
Published: (2024-02-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy
by: Shin-Yu Lu, et al.
Published: (2009-12-01)